
|Articles|November 20, 2013 (Updated: April 18, 2020)
- Immunotherapy (Issue 1)
- Volume 1
- Issue 1
Checkpoint Inhibitors in Cancer Care
Author(s)Jeffrey A. Sosman, MD
Jeffrey A. Sosman, MD, from the Vanderbilt University School of Medicine and Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.
Jeffrey A. Sosman, MD, professor of medicine, director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.
In addition to other immunotherapies, Sosman says he is interested in
Articles in this issue
over 12 years ago
MPDL3280A Induces Durable Responses in NSCLC, Other Cancersover 12 years ago
Immunotherapy—An Increasingly Important Role in Oncologyover 12 years ago
Suzanne Topalian, MD, on PD-1 Targeted Therapyover 12 years ago
PD-1 and PD-L1 Antibodies in Lung Cancerover 12 years ago
Search for Predictive Biomarkers of PD-1 Pathway Blockadeover 12 years ago
Nivolumab Plus Ipilimumab in Advanced Melanomaover 12 years ago
The Outlook for ImmunotherapiesRelated Content
Advertisement



Induction Nivolumab Misses Feasibility Goal in Oropharyngeal Cancer
Published: | Updated:





























